| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
HMG-CoA Reductase (HMGCR). (3S,5R)-Fluvastatin D6 sodium is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway that converts HMG-CoA to mevalonate. By blocking this step, it reduces de novo cholesterol synthesis in the liver, leading to upregulated LDL receptor expression and increased clearance of circulating LDL cholesterol. The D6-labeled version is used as an analytical internal standard and does not contribute to pharmacological activity.
|
|---|---|
| ln Vitro |
Not applicable (internal standard for bioanalysis, not tested in activity assays). The parent drug (3S,5R)-Fluvastatin inhibits HMG-CoA reductase with an IC50 of 8 nM in cell-free enzyme assays. The D6-labeled form has nearly identical chemical and chromatographic properties, allowing it to serve as an internal standard in LC-MS/MS. It is not assessed for biological activity in functional assays.
|
| ln Vivo |
Not applicable (internal standard, not administered as a test article). The parent drug Fluvastatin (3S,5R)-Fluvastatin sodium is used in hypercholesterolemic animal models. Oral administration (0.1-10 mg/kg) lowers plasma total cholesterol and LDL-cholesterol levels by 40-60% in dogs and rats. The D6-labeled version is not evaluated in efficacy studies. It is used as an internal standard for LC-MS/MS quantification of Fluvastatin in pharmacokinetic studies.
|
| Enzyme Assay |
HMG-CoA reductase inhibition is measured using recombinant human HMGCR enzyme (0.1-0.5 U/mL) incubated with [14C]-HMG-CoA (50 microM), NADPH (0.5 mM), and varying concentrations of Fluvastatin (0.1-100 nM) in 100 mM potassium phosphate buffer (pH 7.0) at 37degC for 30-60 minutes. The reaction is terminated by adding 6M HCl, and the product [14C]-mevalonolactone is separated by TLC or extraction and quantified by liquid scintillation. (3S,5R)-Fluvastatin D6 sodium is not used in the inhibition assay; it is used as an internal standard.
|
| Cell Assay |
Not applicable (internal standard, not used in cell-based assays). For quality control of the internal standard, a stock solution of (3S,5R)-Fluvastatin D6 sodium is prepared in methanol or acetonitrile (0.1-1 mg/mL). The solution is injected onto an LC-MS/MS system to verify isotopic purity (>98% D6) and chemical purity (>98%). Chromatographic conditions: C18 column, mobile phase of 0.1% formic acid in water/acetonitrile gradient, ESI negative ionization, MRM transition m/z 416 → 386 (or appropriate D6 mass shift).
|
| Animal Protocol |
Not applicable (internal standard, not administered as a test article in efficacy studies). For pharmacokinetic studies using the internal standard, male Sprague-Dawley rats (200-250 g, n=6) are dosed orally with unlabeled Fluvastatin (3-10 mg/kg). Blood samples are collected at pre-dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose. Plasma is protein-precipitated with acetonitrile containing (3S,5R)-Fluvastatin D6 sodium as the internal standard. Supernatant is injected onto an LC-MS/MS system, and Fluvastatin concentrations are calculated from the peak area ratio. PK parameters (Cmax, Tmax, AUC, t½) are determined.
|
| ADME/Pharmacokinetics |
(3S,5R)-Fluvastatin D6 sodium is a stable isotope-labeled internal standard (SIL-IS) with a mass shift of +6 Da. The parent drug Fluvastatin has an oral bioavailability of approximately 20-30% in humans due to extensive first-pass metabolism (primarily CYP2C9). It is highly protein bound (>98%), with a terminal half-life of approximately 1-2 hours. The D6-labeled version has identical extraction recovery, ionization efficiency, and chromatographic behavior, enabling accurate quantification.
|
| Toxicity/Toxicokinetics |
The D6-labeled version is for research use only and not for human consumption. The parent drug Fluvastatin is generally well tolerated. Common adverse effects include mild GI disturbances (constipation, diarrhea, dyspepsia), headache, and myalgia. Serious but rare side effects include myopathy, rhabdomyolysis (<0.1%), and hepatotoxicity (elevated liver transaminases). Fluvastatin carries a pregnancy category X risk. The D6-labeled version is not administered to humans.
|
| References | |
| Additional Infomation |
(3S,5R)-Fluvastatin D6 sodium is a deuterated internal standard for the quantitative analysis of Fluvastatin in biological matrices using LC-MS/MS. Fluvastatin (Lescol®) was the first fully synthetic statin approved by the FDA in 1993. The D6-labeled version is used in pharmacokinetic studies, bioequivalence trials, and drug-drug interaction assessments (especially with CYP2C9 inhibitors). This compound is a valuable research tool for pharmaceutical analysis and clinical pharmacology.
|
| Molecular Formula |
C24H19D6FNNAO4
|
|---|---|
| Molecular Weight |
439.48
|
| Exact Mass |
439.204
|
| CAS # |
2249799-35-5
|
| Related CAS # |
Fluvastatin;93957-54-1;Fluvastatin sodium;93957-55-2;Fluvastatin-d6 sodium;(3S,5R)-Fluvastatin sodium;94061-81-1;(3S,5R)-Fluvastatin-d6;2249799-34-4
|
| PubChem CID |
76973809
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C(/C1N(C2=CC=CC=C2C=1C1C=CC(F)=CC=1)C(C([2H])([2H])[2H])C([2H])([2H])[2H])=C\[C@H](O)C[C@H](O)CC(=O)[O-].[Na+]
|
| InChi Key |
ZGGHKIMDNBDHJB-WPPSXBOFSA-M
|
| InChi Code |
InChI=1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m0./s1/i1D3,2D3;
|
| Chemical Name |
sodium;(E,3S,5R)-7-[3-(4-fluorophenyl)-1-(1,1,1,3,3,3-hexadeuteriopropan-2-yl)indol-2-yl]-3,5-dihydroxyhept-6-enoate
|
| Synonyms |
(3S,5R)Fluvastatin D6 sodium (3S,5R) Fluvastatin D6 sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2754 mL | 11.3771 mL | 22.7542 mL | |
| 5 mM | 0.4551 mL | 2.2754 mL | 4.5508 mL | |
| 10 mM | 0.2275 mL | 1.1377 mL | 2.2754 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
